A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VUPANORSEN (PF-07285557) IN STATIN-TREATED PARTICIPANTS WITH DYSLIPIDEMIA
- Registry ID
- C4491011
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- PFIZER CANADA ULC
- Start date
- 2020-11-10
- Completion date
- 2022-03-17
- Last update
- 2020-08-20
Conditions
Related clinical trials
- A PHASE-3, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO AND ACTIVE CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH DYSLIPIDEMIA WHO ARE INTOLERANT TO STATINS
- A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR DYSLIPDEMIA AT RISK OF CARDIOVASCULAR EVENTS
- A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF EVOLOCUMAB (AMG 145) IN COMBINATION WITH STATIN THERAPY IN DIABETIC SUBJECTS WITH HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
View on source registry